Valuation
- Market cap
- 420,000,000
- Revenue TTM
- $0
- Net income TTM
- $-126,350,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 100
- Avg volume
- —
- Day's range
- $150,000.00 – $150,000.00
- Shares out
- 3,000
- Stochastic %K
- —
- Beta
- -60.39
- Analysts
- —
- Price target
- —
Company profile
Odonate, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was formerly known as Odonate Therapeutics, Inc. and changed its name to Odonate, Inc. in March 2023. The company was founded in 2013 and is based in New York, New...
Show more
Odonate, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was formerly known as Odonate Therapeutics, Inc. and changed its name to Odonate, Inc. in March 2023. The company was founded in 2013 and is based in New York, New York.
- Industry
- Shell Companies
- Sector
- Financial Services
- Phone
- 332 206 0935
- Website
- https://www.odonate.com
- Address
- 3 East 28th Street, 10th Floor, New York, United States
Latest news
No headlines yet.
